Some La Roche-Posay, Proactiv and Walgreens acne treatments recalled due to benzene levels
U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government ...
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Fierce Pharma20h
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
APP.com (Asbury Park, NJ) on MSN1d
Why La Roche-Posay is pulling this acne treatment, and why you shouldn't use it
Parent company La Roche-Posay has pulled the Effaclar Duo Acne Spot Treatment from L'Oreal's lineup, due to a cancer-causing ...
La Roche-Posay, Proactiv, Walgreens skin care products voluntarily recalled over potentially cancer-causing chemical
Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated levels of a potentially cancer-causing agent.
Some acne treatments from brands like Walgreens, La Roche-Posay voluntarily recalled
The FDA tested 95 products containing benzoyl peroxide, an ingredient widely used to treat acne that can form benzene as a byproduct. It found that six products could have more benzene than usual.
Fierce Biotech3d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Medical Marketing & Media2d
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...